Durable survival in late-stage cancer
Biomarkers validating response
Early Phase 3 momentum building
In a space where options are limited, long-term survivor cohorts matter.
#Biotech #ASCO2026
NEWS: https://bit.ly/3Se0RRi
Source: https://investorshangout.com/post/newpost/69106/